Esterline (ESL) was upgraded to buy at Drexel Hamilton. $86 price target. Margins will likely recover in the coming quarters, Drexel said.
Valeant Pharmaceuticals (VRX) was upgraded to neutral from underperform at Mizuho. $25 price target. The valuation is more attractive, given new guidance and based on sum-of-the-parts, Mizuho said.